Zinc Gluconate
drugOn this page
Also known as Bis(d-gluconato-o1,o2) zincGluconic acid zinc complexZinc d-gluconate (1:2)Zincum gluconicum
Summary
Zinc Gluconate (CHEMBL3833377) is an approved small molecule (ATC A12CB02); indicated across 4 conditions including type 2 diabetes mellitus and spasmodic dystonia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A12CB02
- Indications: 4 conditions
- Clinical trials: 23
- Chemistry: 455.7 Da · C12H22O14Zn
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3833377 |
| Name | Zinc Gluconate |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 443445 |
| ATC | A12CB02 |
| Molecular formula | C12H22O14Zn |
| Molecular weight | 455.7 |
| InChIKey | WHMDKBIGKVEYHS-IYEMJOQQSA-L |
SMILES: C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Zn+2]
IUPAC name: zinc bis((2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate)
Also known as: Bis(d-gluconato-o1,o2) zinc, Gluconic acid zinc complex, Zinc d-gluconate (1:2), Zinc gluconate, Zincum gluconicum, ZINC GLUCONATE
Patent coverage: 11,895 distinct patent families (24,616 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 2 diabetes mellitus | 2 | MONDO:0005148 | MONDO:0005148 |
| spasmodic dystonia | 1 | MONDO:0000485 | MONDO:0000485 |
| Wilson disease | 0 | MONDO:0010200 | MONDO:0010200 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 23.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 13 |
| PHASE2/PHASE3 | 3 |
| PHASE4 | 2 |
| EARLY_PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05835037 | PHASE4 | RECRUITING | Effect of Zinc on Glucose Homeostasis |
| NCT05096312 | PHASE4 | COMPLETED | Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients |
| NCT01309620 | PHASE2/PHASE3 | COMPLETED | Zinc Supplementation in Type 2 Diabetics |
| NCT01783353 | PHASE2/PHASE3 | COMPLETED | Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial |
| NCT05527899 | PHASE2/PHASE3 | COMPLETED | Zinc Intervention in Elderly for Prevention of Pneumonia |
| NCT06120140 | PHASE2 | ACTIVE_NOT_RECRUITING | Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib |
| NCT00692224 | PHASE1/PHASE2 | COMPLETED | Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial |
| NCT01984580 | PHASE1 | UNKNOWN | Effect of Zinc on Barrett’s Metaplasia |
| NCT03957720 | EARLY_PHASE1 | UNKNOWN | The Individual Therapy for Patients With Wilson’s Disease |
| NCT05085834 | EARLY_PHASE1 | COMPLETED | Zinc Effect on Inflammation and Cardiovascular Risk in HIV |
| NCT05853692 | Not specified | RECRUITING | Prevention of Oral Mucositis in Head and Neck Cancer. |
| NCT06577285 | Not specified | RECRUITING | The Effect Of Botox In Patients With Gummy Smile With And Without Zinc And Phytase Supplementation. |
| NCT01576627 | Not specified | COMPLETED | Zinc Absorption From Zinc Citrate, Zinc Gluconate and Zinc Oxide |
| NCT01934803 | Not specified | COMPLETED | Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort |
| NCT02475928 | Not specified | UNKNOWN | Zinc Supplementation in Cirrhotic Patients |
| NCT02520817 | Not specified | COMPLETED | Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study |
| NCT02856269 | Not specified | COMPLETED | Zinc Supplementation and Cardiovascular Risk in HIV |
| NCT02951715 | Not specified | COMPLETED | Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss |
| NCT04342728 | Not specified | COMPLETED | Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation |
| NCT04351490 | Not specified | WITHDRAWN | Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19 |
| NCT04558424 | Not specified | UNKNOWN | RCT,Double Blind, Placebo to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU |
| NCT05098678 | Not specified | COMPLETED | Zinc Supplementation and Behçet’s Syndrome |
| NCT05597137 | Not specified | COMPLETED | The Exploration of the Regulatory Effect of Zinc on Intestinal Flora in Healthy Adults |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.